Payment overview · 2025
General Payments
$1,572.24
63 reported records · 14 companies
Healthcare provider profile · identity verified
Carmine V Oddis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MACON, GA · NPI 1659315737
Verified facts
What the public records show
CMS Open Payments records show Carmine V Oddis, M.D. received $1,572.24 in general payments during 2025 across 63 reported records.
Abbott Laboratories accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1672 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1672 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $233.04 | 14.8% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$231.85 | 14.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $219.50 | 14.0% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $193.17 | 12.3% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $168.33 | 10.7% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.03 | 10.2% | 3 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $104.24 | 6.6% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $92.79 | 5.9% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $74.14 | 4.7% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $33.57 | 2.1% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $19.40 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.85 | 1.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.34 | 1.1% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $5.99 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,572.24 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $212.78 | 6 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $172.61 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $168.33 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $161.03 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $138.80 | 8 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $133.90 | 6 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $104.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $99.55 | 6 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $92.79 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $60.19 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $33.33 | 4 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $12.40 | 1 | 2025 |
Source payment records
|
|||||
| FLEXCATH CONTOUR Normalized: flexcath contour |
Device | Medtronic, Inc. | $12.33 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $11.66 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $11.23 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $8.78 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $8.64 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $5.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1672 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1672 | 332 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1672 | 332 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1672 | 332 |
| Flecainide Acetate | Flecainide Acetate | 1453 | 368 |
| Amiodarone Hcl | Amiodarone Hcl | 792 | 251 |
| Metoprolol Succinate | Metoprolol Succinate | 690 | 189 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 630 | 195 |
| Xarelto | Rivaroxaban | 585 | 110 |
| Methylphenidate Hcl | Methylphenidate Hcl | 435 | 133 |
| Furosemide | Furosemide | 417 | 124 |
| Entresto | Sacubitril/Valsartan | 392 | 88 |
| Propafenone Hcl | Propafenone Hcl | 371 | 91 |
| Digoxin | Digoxin | 316 | 76 |
| Midodrine Hcl | Midodrine Hcl | 291 | 92 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 284 | 74 |
| Losartan Potassium | Losartan Potassium | 276 | 76 |
| Carvedilol | Carvedilol | 266 | 69 |
| Cephalexin | Cephalexin | 250 | 236 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 72 |
| Sotalol | Sotalol Hcl | 247 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 245 | 67 |
| Tramadol Hcl | Tramadol Hcl | 229 | 223 |
| Prazosin Hcl | Prazosin Hcl | 214 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 200 | 54 |
| Nifedipine Er | Nifedipine | 169 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 46 |
| Meclizine Hcl | Meclizine Hcl | 148 | 54 |
| Lisinopril | Lisinopril | 147 | 49 |
| Warfarin Sodium | Warfarin Sodium | 127 | 41 |
| Spironolactone | Spironolactone | 113 | 34 |
| Mexiletine Hcl | Mexiletine Hcl | 111 | 32 |
| Potassium Chloride | Potassium Chloride | 106 | 29 |
| Farxiga | Dapagliflozin Propanediol | 104 | 25 |
| Pindolol | Pindolol | 103 | 31 |
| Dofetilide | Dofetilide | 95 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 94 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 28 |
| Acebutolol Hcl | Acebutolol Hcl | 89 | 20 |
| Verapamil Er | Verapamil Hcl | 81 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 22 |
| Desmopressin Acetate | Desmopressin Acetate | 76 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 22 |
| Labetalol Hcl | Labetalol Hcl | 64 | 19 |
| Levofloxacin | Levofloxacin | 52 | 46 |
| Propafenone Hcl Er | Propafenone Hcl | 52 | 14 |
| Bumetanide | Bumetanide | 46 | 13 |
| Diazepam | Diazepam | 46 | 14 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 12 |
| Simvastatin | Simvastatin | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Atenolol | Atenolol | 33 | 12 |
| Nitroglycerin | Nitroglycerin | 33 | 15 |
| Pradaxa | Dabigatran Etexilate Mesylate | 30 | suppressed |
| Minoxidil | Minoxidil | 29 | 13 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Multaq | Dronedarone Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 26 | suppressed |
| Nadolol | Nadolol | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Pacerone | Amiodarone Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Opsumit | Macitentan | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,572.24 · 63 records | Abbott Laboratories | AFFERA MAPPING SYSTEM, AURORA EV-ICD MRI SURESCAN, AVEIR, Assure WCD, CAMZYOS, CAPVAXIVE, CARDIOMEMS, CARDIVA VASCADE MVP XL VVCS 10-12F, ELIQUIS, FARAPULSE, FARXIGA, FLEXCATH CONTOUR, General - Brady, IN.PACT ADMIRAL, Kerendia, LINQ II, LUX-Dx Insertable Cardiac Monitor, LifeVest, NURTEC ODT, PULSESELECT, REPATHA, RHYTHM EXPRESS, VERQUVO, VYNDAQEL, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error